Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study

Small-cell lung cancer (SCLC) is a highly lethal subtype of lung cancer. Despite concerted efforts over the past several decades, there have been limited therapeutic advances. Traditional chemotherapy offers a high response rate and rapid symptomatic improvement, but its benefit is fleeting, and relapse is quick and unforgiving. Immunotherapy has delivered improved outcomes for patients with many cancers and there was compelling rationale for development in SCLC. While initial efforts with cytotoxic T-lymphocyte protein-4 inhibitors failed to improve upon chemotherapy alone, the addition of programmed death ligand-1 (PD-L1) inhibitors to first-line chemotherapy finally provided long-awaited gains in survival. Atezolizumab, when added to carboplatin and etoposide, improved both progression-free survival and overall survival. Durvalumab, when added to platinum plus etoposide, similarly improved OS. Biomarker development has stalled as PD-L1 expression and tumor mutational burden have not been useful predictive biomarkers. However, based on the significant survival improvements, both atezolizumab and durvalumab were approved by the US Food and Drug Administration to be given with first-line chemotherapy, and these regimens represent the new standards of care for SCLC.

Download Full-text

Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e3182a406a3 ◽

2013 ◽

Vol 8 (10) ◽

pp. 1255-1264 ◽

Cited By ~ 24

Author(s):

Bjørn H. Grønberg ◽

Marius Lund-Iversen ◽

Erik H. Strøm ◽

Odd Terje Brustugun ◽

Helge Scott

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Line Chemotherapy

Download Full-text

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer

OncoImmunology ◽

10.1080/2162402x.2017.1339856 ◽

2017 ◽

Vol 6 (9) ◽

pp. e1339856 ◽

Cited By ~ 6

Author(s):

Courèche-Guillaume Kaderbhai ◽

Corentin Richard ◽

Jean David Fumet ◽

Anne Aarnink ◽

Sandra Ortiz-Cuaran ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Chemotherapy Regimen ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Line Chemotherapy

Download Full-text

Neutropenia-Related Costs in Patients Treated with First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

Journal of Managed Care Pharmacy ◽

10.18553/jmcp.2009.15.8.669 ◽

2009 ◽

Vol 15 (8) ◽

pp. 669-682 ◽

Cited By ~ 9

Author(s):

Michael E. Stokes ◽

Catherine E. Muehlenbein ◽

Martin D. Marciniak ◽

Douglas E. Faries ◽

Saeed Motabar ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Line Chemotherapy

Download Full-text

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

BMC Cancer ◽

10.1186/s12885-021-08977-0 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Hao-chuan Ma ◽

Yi-hong Liu ◽

Kai-lin Ding ◽

Yu-feng Liu ◽

Wen-jie Zhao ◽

...

Keyword(s):

Lung Cancer ◽

Adverse Events ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Treatment Options ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Grade 3

Abstract Background Whereas there are many pharmacological interventions prescribed for patients with advanced anaplastic lymphoma kinase (ALK)- rearranged non-small cell lung cancer (NSCLC), comparative data between novel generation ALK-tyrosine kinase inhibitors (TKIs) remain scant. Here, we indirectly compared the efficacy and safety of first-line systemic therapeutic options used for the treatment of ALK-rearranged NSCLC. Methods We included all phase 2 and 3 randomised controlled trials (RCTs) comparing any two or three treatment options. Eligible studies reported at least one of the following outcomes: progression free survival (PFS), overall survival (OS), objective response rate (ORR), or adverse events of grade 3 or higher (Grade ≥ 3 AEs). Subgroup analysis was conducted according to central nervous system (CNS) metastases. Results A total of 9 RCTs consisting of 2484 patients with 8 treatment options were included in the systematic review. Our analysis showed that alectinib (300 mg and 600 mg), brigatinib, lorlatinib and ensartinib yielded the most favorable PFS. Whereas there was no significant OS or ORR difference among the ALK-TKIs. According to Bayesian ranking profiles, lorlatinib, alectinib 600 mg and alectinib 300 mg had the best PFS (63.7%), OS (35.9%) and ORR (37%), respectively. On the other hand, ceritinib showed the highest rate of severe adverse events (60%). Conclusion Our analysis indicated that alectinib and lorlatinib might be associated with the best therapeutic efficacy in first-line treatment for major population of advanced NSCLC patients with ALK-rearrangement. However, since there is little comparative evidence on the treatment options, there is need for relative trials to fully determine the best treatment options as well as the rapidly evolving treatment landscape.

Download Full-text